# A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer

Source: https://onco.cc/trials/nct02152631/  
OnCo record `nct02152631` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Abemaciclib, Erlotinib in non-small-cell lung cancer and small-cell lung cancer, run by Eli Lilly and Company, active and no longer recruiting.

## Summary

A Study of Abemaciclib (LY2835219) in Participants With Previously Treated KRAS Mutated Lung Cancer is a phase 3 interventional study registered as NCT02152631 by Eli Lilly and Company, with 453 participants enrolled, started 2014-10-03 and due to reach its primary completion in 2017-09-15. Interventions recorded: Abemaciclib, Erlotinib. Conditions listed: Non Small Cell Lung Cancer. Results were posted on ClinicalTrials.gov in 2018; the figures recorded here are the registry's, not a publication's.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-22
- Also known as: JUNIPER
- Tags: ctgov-ingest
- Registry id: NCT02152631
- Phase: 3
- Setting: JUNIPER: A Randomized Phase 3 Study of Abemaciclib Plus Best Supportive Care Versus Erlotinib Plus Best Supportive Care in Patients With Stage IV NSCLC With a Detectable KRAS Mutation Who Have Progressed After Platinum-Based Chemotherapy
- Sponsor: Eli Lilly and Company
- Enrolled: 453
- Outcomes: Overall Survival (OS): Abemaciclib 7.4 months vs Erlotinib 7.8 months, HR 0.968; Progression Free Survival (PFS): Abemaciclib 3.6 months vs Erlotinib 1.9 months, HR 0.583; Percentage of Participants With Complete Response (CR) or Partial Response (PR) (Objective Response Rate [ORR]): Abemaciclib 8.9% vs Erlotinib 2.7%

## Sources

- ClinicalTrials.gov NCT02152631: https://clinicaltrials.gov/study/NCT02152631

## Connected records

- cancers: [Non-small-cell lung cancer](https://onco.cc/cancers/nsclc/), [Small-cell lung cancer](https://onco.cc/cancers/sclc/)
- technologies: [CDK4/6 inhibitors](https://onco.cc/technologies/cdk46-inhibitor/), [Small-molecule kinase inhibitors](https://onco.cc/technologies/kinase-inhibitors/)
- drugs: [Abemaciclib](https://onco.cc/drugs/abemaciclib/), [Erlotinib](https://onco.cc/drugs/erlotinib/)
- companies: [Eli Lilly (incl. Loxo)](https://onco.cc/companies/eli-lilly/)
- key papers: [A Randomized Phase III Study of Abemaciclib Versus Erlotinib in Patients with Stage IV Non-small Cell Lung Cancer With a Detectable KRAS Mutation Who Failed Prior Platinum-Based Therapy: JUNIPER](https://onco.cc/key-papers/paper-nct02152631-front-oncol-2020/)

---
JSON: https://onco.cc/api/v1/entities/nct02152631.json